Conduit C, Hutchinson AD, Leonard M, O.’Haire S, Moody M, Thomas B, Sim I, Hong W, Ahmad G, Lawrentschuk N, Lewin J, Tran B, Dhillon HM. An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial. Journal of Cancer Survivorship. 2025;19(2):10.1007/s11764-023-01489-9
Eifer M, Sutherland DEK, Goncalves I, Buteau JP, Au L, Azad AA, Emmett L, Kong G, Kostos L, Ravi Kumar AS, Kwan EM, Medhurst E, Sandhu S, Tran B, Wyatt AW, Hofman MS. Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.268640
Udovicich C, Bressel M, Manji J, Ali M, Au L, Azad AA, Buteau JP, Chander S, Chang D, Eapen R, Lawrentschuk N, Levy SM, Moon D, Murphy DG, Perera M, Shaw M, Spain L, Tran B, Hofman MS, Siva S. PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.268639
Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.Journal of Nuclear Medicine. 2025;66(4):10.2967/jnumed.124.269252
Abdul Aziz N, Ng K, Alifrangis C, Tran B, Conduit C, Liow ECH, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart RA, Reid AH, Shamash J, Rajan P. THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.Journal of Clinical Oncology. 2025;43(5_suppl):10.1200/jco.2025.43.5_suppl.tps651
Hansen AR, Zhang AY, Boni V, Mantia C, Yu EY, Weickhardt AJ, Robert M, Gupta S, Morales-Barrera R, Hoimes CJ, Berlin J, Iyer G, Millward M, Lihou CF, Loriot Y, Pouessel D, Mittal K, Hill AG, Racca F, Tran B. A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).Journal of Clinical Oncology. 2025;43(5_suppl):10.1200/jco.2025.43.5_suppl.tps904
Mak B, Tran B, Thomas H, Pashankar FD, Hansen AR, Feldman DR, Huddart RA, Wheater M, Dunwoodie E, Mazhar D, Lawrence NJ, Stevanovic AG, Birtle AJ, Oladipo O, Wyld D, Balagtas JMS, Stockler MR, Grimison PS. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).Journal of Clinical Oncology. 2025;43(5_suppl):10.1200/jco.2025.43.5_suppl.tps653
Liu J, Hiwase M, Woon DTS, Thomas B, Tran B, Lawrentschuk N. Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review. BJU International. 2025;135(2):10.1111/bju.16536
Panian J, Zhong C, Choi SH, Ly K, Quinn R, Ferrier E, Saad E, Saliby RM, Malvar C, Pal S, Ebrahimi H, Tran B, Jude E, Lalani A-K, Suarez C, Velasco GD, Kanesvaran R, Zarba M, Liow E, El Hajj Chehade R, Choueiri TK, Heng DYC, McKay RR. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. European Urology Focus. 2024;:10.1016/j.euf.2024.11.011
Hitchen N, Shahnam A, Manoharan S, Topp M, Mileshkin L, Lim AM, Whittle JR, Luen SJ, Solomon B, Lackovic K, Desai J, Tran B. Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022. Asia-Pacific Journal of Clinical Oncology. 2024;20(6):10.1111/ajco.14100
